Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group.
about
Ascorbic acid for the treatment of Charcot-Marie-Tooth diseaseTreatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infectionTreatment for IgG and IgA paraproteinaemic neuropathyImmunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathiesTreatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infectionTreatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviewsIntravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathyIntravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathyTreatment for Charcot-Marie-Tooth diseaseImmunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathiesTreatment for Charcot-Marie-Tooth diseaseTreatment for IgG and IgA paraproteinaemic neuropathyTreatment for IgG and IgA paraproteinaemic neuropathyImmunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathiesTreatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trialConnecting impairment, disability, and handicap in immune mediated polyneuropathiesPlacebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathyIntravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial.The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational studyClinimetric evaluation of a new overall disability scale in immune mediated polyneuropathiesA randomized trial of diagnostic ultrasound to improve outcomes in focal neuropathies.Treatment of Guillain-Barré syndrome and CIDP.Metabolic Syndrome, Neurotoxic 1-Deoxysphingolipids and Nervous Tissue Inflammation in Chronic Idiopathic Axonal Polyneuropathy (CIAP)The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority studyOutcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials.Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.Crosswalk of participation self-report measures for aphasia to the ICF: what content is being measured?Thalidomide causes sinus bradycardia in ALS.Pain and Physical Functioning in Neuropathic Pain: A Systematic Review of Psychometric Properties of Various Outcome Measures.Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trialNerve ultrasound as follow-up tool in treated multifocal motor neuropathy.Assessment scales for the diagnosis of polyneuropathy.Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospective study.Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
P2860
Q24187132-2DF62CDE-8C03-4337-A5DD-5D1C62B8480DQ24187162-F21537D7-4945-45B5-96A4-8ED0A8B7EF1DQ24187168-DCE3BBB2-95D0-46D1-9865-740DD036C77FQ24197877-015A0598-88BC-4172-BAE0-233B8951CC93Q24201259-28A81D94-79E9-40CA-B4F5-FF32FF4B13D9Q24201434-27C53609-94F6-43D4-8F39-DC3C3F361DE8Q24201573-9CECB5FB-39C6-403C-99A5-704E58728D94Q24240936-759D6690-4C06-4542-969E-5C609BDBF829Q24242777-E04EAED1-D772-4FCB-BEF4-DA680C7EDD8EQ24243918-F8E520CA-2412-42A0-8581-9FBD7B83192FQ24244335-25544AC2-140E-4C62-8616-E61B5BF72AFEQ24246371-3CD7B93D-09DB-4C06-BE9C-E61AF59541E6Q24246682-FD8B1FFC-D42D-4B0E-B2BE-07A039F74840Q24250235-6F868825-AC48-48AA-860D-23B60B8E4B6FQ30397454-A2083964-36FD-45DF-AE9A-E1F6AB879441Q30818191-322C7680-E6B7-4027-ABC3-ECFE708098A6Q30883545-3393D1C9-DE5B-4CD4-9B50-66646C460F7DQ33185473-E8A1237A-2410-4649-AA08-13340FFBA84FQ34344264-CA8B5F63-982D-4A12-B982-C823D9891400Q34699002-42B73D09-8ED3-4749-8864-516F0C4C83ABQ34978167-BED9BEE6-D890-44C0-94B2-304BE09FC418Q35107092-16E5039E-AD4E-41E5-B235-A80B7DAA8C20Q35467350-5F2008E7-4F66-47F4-92C7-F9E8758E769FQ36132844-02ADC8A2-DAEC-421C-BF4D-3887EC8D2D1AQ36164126-C4C9F260-FE98-40D7-AB47-A213E884618DQ36257577-B37402C9-F12C-4EDF-A6AA-87696324FEFBQ36551631-B3D6D5F2-C0EF-4C70-A584-5EFE78FCEFE3Q36556379-2493D29F-589A-4546-B622-42303CF91847Q37207302-790C9327-9F70-410D-AFA3-10E2494EEA5DQ37339743-2D21E0D7-5B2E-4EF2-AAAD-C0EAC7B4D2C2Q37557375-28E6CF63-EE8B-485B-B660-CCC4B0012513Q38243974-F8FCF0DB-FE2E-4E86-B991-0C32A9F05136Q38390908-35C1B775-9D25-4B8E-A8AA-6452BCB0C3B9Q38417354-B28F0BC3-3408-4787-A5B3-D269A7C5B82DQ38646013-4CD7AB2E-CB96-4972-BB99-C15C0FA88101Q38691659-342C8011-A7EB-45D2-AB5B-FC55703C159AQ38770566-B52AEA97-8564-4E6F-B7B9-043409CF5F60Q38958436-75607504-5711-4130-B792-765DB6841F47Q38971983-C4466655-5ADD-405B-9DCA-8A064C4B27FAQ39091509-BEDA97E2-4A22-4C3F-BC82-508C688C6263
P2860
Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Psychometric evaluation of a n ...... e and Treatment (INCAT) Group.
@ast
Psychometric evaluation of a n ...... e and Treatment (INCAT) Group.
@en
type
label
Psychometric evaluation of a n ...... e and Treatment (INCAT) Group.
@ast
Psychometric evaluation of a n ...... e and Treatment (INCAT) Group.
@en
prefLabel
Psychometric evaluation of a n ...... e and Treatment (INCAT) Group.
@ast
Psychometric evaluation of a n ...... e and Treatment (INCAT) Group.
@en
P2093
P356
P1433
P1476
Psychometric evaluation of a n ...... e and Treatment (INCAT) Group.
@en
P2093
Merkies IS
Schmitz PI
van Doorn PA
P304
P356
10.1212/WNL.54.4.943
P407
P577
2000-02-01T00:00:00Z